1-甲基-3-(甲基氨基甲基)哌啶双盐酸盐 | 639078-61-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-甲基-3-(甲基氨基甲基)哌啶双盐酸盐
• 英文名称: N-methyl-1-(1-methylpiperidin-3-yl)methanamine
• CAS: 639078-61-8
• 化学式: C₈H₁₈N₂
• mdl: MFCD05864531
• 分子量: 142.244
• InChiKey: OUBNEVZXIXKNJE-UHFFFAOYSA-N

物化性质

• 沸点：
  172.1±8.0 °C(Predicted)
• 密度：
  0.867±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-甲基-3-(甲基氨基甲基)哌啶双盐酸盐 在 PS-carbodiimide resin 、 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 24.33h， 生成 3-Cyclohexyl-2-(3-fluorophenyl)-1-[2-[methyl-[(1-methylpiperidin-3-yl)methyl]amino]-2-oxoethyl]indole-6-carboxylic acid
  参考文献：
  名称：

  Potent Inhibitors of Subgenomic Hepatitis C Virus RNA Replication through Optimization of Indole-N-Acetamide Allosteric Inhibitors of the Viral NS5B Polymerase

  摘要：

  Infections caused by hepatitis C virus (HCV) are a significant world health problem for which novel therapies are in urgent demand. Compounds that block replication of subgenomic HCV RNA in liver cells are of interest because of their demonstrated antiviral effect in the clinic. In followup to our recent report that indole-N-acetamides (e.g., 1) are potent allosteric inhibitors of the HCV NS513 polymerase enzyme, we describe here their optimization as cell-based inhibitors. The crystal structure of 1 bound to NS513 was a guide in the design of a two-dimensional compound array that highlighted that formally zwitterionic inhibitors have strong intracellular potency and that pregnane X receptor (PXR) activation (an undesired off-target activity) is linked to a structural feature of the inhibitor. Optimized analogues devoid of PXR activation (e.g., 55, EC50 = 127 nM) retain strong cell-based efficacy under high serum conditions and show acceptable pharmacokinetics parameters in rat and dog.

  DOI：

  10.1021/jm050056+
• 作为产物：
  描述：

  3-(氯甲基)-1-甲基哌啶 、 甲胺 在 水 、 二氯甲烷 、 magnesium sulfate 作用下， 以 乙醇 为溶剂， 反应 17.0h， 以to yield the title product, 8.2 g的产率得到1-甲基-3-(甲基氨基甲基)哌啶双盐酸盐
  参考文献：
  名称：

  NOVEL PHARMACEUTICALS

  摘要：

  该发明涉及式(I)的化合物。

  公开号：

  US20070270412A1

文献信息

• [EN] 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 2-CYANOISOINDOLINE POUR LE TRAITEMENT DU CANCER
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2017158388A1

  公开（公告）日：2017-09-21

  The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to methods for the preparation of these compounds and to their use in the treatment of cancer.

  这项发明涉及公式I的新化合物，这些化合物是去泛素化酶（DUBs）和/或去泛素化酶的抑制剂。具体来说，该发明涉及抑制泛素C端水解酶7或泛素特异性肽酶7（USP7）。该发明还涉及这些化合物的制备方法以及它们在癌症治疗中的应用。
• [EN] HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE MER
  申请人：DONG A SOCIO HOLDINGS CO LTD

  公开号：WO2018071343A1

  公开（公告）日：2018-04-19

  Compounds of formula (I) [Formula should be inserted here] and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventing Mer tyrosine kinase receptor modulated disease or conditions. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  式(I)的化合物及其药学上可接受的盐，其中A、R1、R2、R3、R4、R5、R6、R7、R24、X、L、n和p如规范中定义的那样，可用于治疗或预防Mer酪氨酸激酶受体调节的疾病或症状。还描述了式(I)的化合物的药物组合物，以及使用这些化合物和组合物的方法。
• [EN] 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS<br/>[FR] INHIBITEURS 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DE PHD
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2014160810A1

  公开（公告）日：2014-10-02

  The present invention provides compounds of formula (I) which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.

  本发明提供了公式(I)的化合物，这些化合物可用作PHD的抑制剂，以及与HIF相关疾病的治疗方法，制备这些化合物及其中间体的药物组合物。
• HETEROARYLS AND USES THEREOF
  申请人：MILLENNIUM PHARMACEUTICALS, INC.

  公开号：US20130165464A1

  公开（公告）日：2013-06-27

  This invention provides compounds of formula IB: and also provides compounds of formulas ID, IIB, VB, and IIC: wherein HY, R 1 , R 2 , G 5 , G 6 , G 7 , G 8 , and G 9 are as described in the specification. The compounds are inhibitors of VPS34 and/or PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

  这项发明提供了以下式IB的化合物： 并且还提供了以下式ID、IIB、VB和IIC的化合物： 其中HY、R1、R2、G5、G6、G7、G8和G9如规范中所述。这些化合物是VPS34和/或PI3K的抑制剂，因此对于治疗增殖性、炎症性或心血管疾病是有用的。
• [EN] THIENOPYRROLES AS ANTIVIRAL AGENTS<br/>[FR] THIENOPYRROLES UTILISES COMME AGENTS ANTIVIRAUX
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2005023819A1

  公开（公告）日：2005-03-17

  The present invention relates to thienopyrrole compounds of formula (I); wherein A, B, Y, Ar, n, Z and X1 are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections.

  本发明涉及式(I)的噻吡咯烷化合物；其中A、B、Y、Ar、n、Z和X1如本文所定义，并且其药学上可接受的盐，在预防和治疗丙型肝炎感染中有用。